SEC Filings >


2|7|12
Radius Health, Inc. Files Registration Statement for Proposed Public Offering


12|21|11
Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis


12|16|11
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing


12|5|11
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy


11|23|11
Radius Closes $27.65 Million Second Tranche of Previously Announced Financing


5|24|11
Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study


5|24|11
Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis


6|19|10
Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes


8|5|09
Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis


3|24|09
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes


11|20|08
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million


6|9|08
Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions


4|2|08
Radius Completes Enrollment of Phase 2 Clinical Trial of BA058 for Osteoporosis


1|30|08
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes


Press Releases 2004-2007 >